middle-of-the-night awakening

middle-of-the-night awakening

Insomnia characterised by a difficulty in returning to sleep once awakened after going to sleep for the night and before getting up at one’s usual time in the morning. MOTN awakening is associated with excessive daytime sleepiness and fatigue.

Frequency
Occurs in one-third of the general population at least three nights/week.

Aetiology
Anxiety, obstructive sleep apnoea, chronic pain, pregnancy, toilet needs, depression, bipolar disorder, obesity, hypertension, heart disease, alcohol consumption, menopause, etc.

Management
No medication is consistently effective.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
On 23 November 2011, the FDA approved Intermezzo sublingual tablet C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty in returning to sleep.
The US Food Drug Administration (FDA) had reportedly approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
A review of store shelves showed her that there were no products available to address middle-of-the-night awakening, the sleep problem she shares with an estimated 70 million Americans.
This application was based on the results of two pivotal Phase 3 clinical studies in patients with insomnia, SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303), enrolling approximately 2,000 patients, as well as important safety studies, including assessment of postural stability after middle-of-the-night awakening and a next-morning driving study.
In addition, the company said the middle-of-the-night awakening with difficulty falling back to sleep is a common sleep problem and Intermezzo is the first and only prescription sleep aid approved for dosing in the middle of the night to treat this form of insomnia.
24 November 2011 - US Transcept Pharmaceuticals Inc (NASDAQ:TSPT) said on Wednesday the US Food and Drug Administration (FDA) had approved Intermezzo (zolpidem tartrate sublingual tablet) C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Pharmaceutical company Transcept Pharmaceuticals Inc (Nasdaq:TSPT) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for Intermezzo C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
The recommended doses of Intermezzo[R], a lower-dose zolpidem product approved for middle-of-the-night awakenings, has not changed.